INTRODUCTION: Blood-based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large-scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. METHODS: We investigated whether plasma concentrations of the Aβ1-40/Aβ1-42 ratio, assessed using the single-molecule array (Simoa) immunoassay, may predict brain Aβ positron emission tomography status in a large-scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis-driven investigation followed by a no-a-priori hypothesis study using machine learning. RESULTS: The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ1-40/Aβ1-42 ratio. The accuracy is not affected by the apolipoprotein E (APOE) ε4 allele, sex, or age. DISCUSSION: Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ1-40/Aβ1-42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design.
|Autori:||Vergallo, Andrea; Mégret, Lucile; Lista, Simone; Cavedo, Enrica; Zetterberg, Henrik; Blennow, Kaj; Vanmechelen, Eugeen; De Vos, Ann; Habert, Marie-Odile; Potier, Marie-Claude; Dubois, Bruno; Neri, Christian; Hampel, Harald; Giorgi, FILIPPO SEAN|
|Titolo:||Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease|
|Anno del prodotto:||2019|
|Digital Object Identifier (DOI):||10.1016/j.jalz.2019.03.009|
|Appare nelle tipologie:||1.1 Articolo in rivista|